Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-14.16 Insider Own6.83% Shs Outstand7.48M Perf Week-11.84%
Market Cap2.12M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.96M Perf Month-34.19%
Income-40.45M PEG- EPS next Q- Inst Own10.47% Short Float / Ratio2.29% / 0.42 Perf Quarter-57.80%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Interest0.16M Perf Half Y-76.22%
Book/sh-0.02 P/B- EPS next Y- ROA-205.89% Target Price80.00 Perf Year-96.60%
Cash/sh0.36 P/C0.80 EPS next 5Y- ROE-312.04% 52W Range0.26 - 9.00 Perf YTD-91.65%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-96.86% Beta-
Dividend %- Quick Ratio0.70 Sales past 5Y0.00% Gross Margin- 52W Low9.69% ATR0.06
Employees5 Current Ratio0.70 Sales Q/Q- Oper. Margin0.00% RSI (14)34.90 Volatility23.71% 17.68%
OptionableNo Debt/Eq- EPS Q/Q88.23% Profit Margin- Rel Volume1.72 Prev Close0.27
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume377.02K Price0.28
Recom1.00 SMA20-23.11% SMA50-38.89% SMA200-74.28% Volume649,499 Change4.43%
Date Action Analyst Rating Change Price Target Change
Sep-15-21Initiated Maxim Group Buy $11
Nov-28-23 09:00AM
Aug-14-23 04:29PM
Aug-10-23 08:46AM
Aug-07-23 09:00AM
Aug-03-23 08:00AM
08:00AM Loading…
Jul-31-23 08:00AM
Apr-10-23 04:30PM
Apr-05-23 01:00PM
Feb-27-23 08:30AM
Feb-23-23 07:30AM
Feb-22-23 04:30PM
Jan-25-23 08:45AM
Jan-17-23 08:00AM
Jan-05-23 08:30AM
Jan-04-23 08:30AM
08:30AM Loading…
Dec-29-22 08:30AM
Dec-23-22 08:00AM
Dec-20-22 02:11PM
Dec-16-22 09:00AM
Nov-30-22 05:00PM
Nov-21-22 08:30AM
Nov-15-22 12:37PM
Sep-26-22 08:30AM
Aug-22-22 08:30AM
Jul-27-22 08:30AM
Jul-21-22 08:00AM
Jul-18-22 08:30AM
Jun-22-22 04:05PM
Jun-14-22 04:15PM
08:30AM Loading…
May-31-22 08:30AM
May-02-22 08:00AM
Apr-29-22 06:32PM
Feb-17-22 08:30AM
Jan-31-22 08:00AM
Dec-28-21 11:00AM
Dec-15-21 08:15AM
Dec-12-21 06:06AM
Dec-10-21 05:15PM
Dec-06-21 08:15AM
Dec-01-21 02:45PM
Nov-22-21 08:30AM
Nov-18-21 08:15AM
Nov-03-21 12:06PM
Oct-26-21 08:30AM
Sep-30-21 08:30AM
Sep-20-21 08:00AM
Aug-30-21 08:30AM
Aug-24-21 08:30AM
Aug-19-21 09:00AM
Aug-02-21 08:00AM
Jul-29-21 08:00AM
Jul-28-21 08:15AM
Jul-20-21 08:00AM
Jul-12-21 09:51AM
Jul-07-21 08:00AM
Jun-28-21 08:15AM
Jun-10-21 09:12AM
Jun-01-21 08:00AM
May-28-21 08:00AM
May-21-21 04:45PM
Apr-20-21 08:00AM
Apr-19-21 05:00PM
Apr-14-21 08:15AM
Mar-26-21 08:30AM
Mar-25-21 08:30AM
Mar-24-21 08:30AM
Mar-08-21 01:30PM
Feb-24-21 04:00PM
Feb-19-21 09:00AM
Feb-17-21 12:00AM
Jan-11-21 08:00AM
Jan-05-21 02:50PM
Dec-03-20 11:08AM
Nov-24-20 10:00AM
Nov-23-20 08:30AM
Nov-17-20 08:00AM
Nov-10-20 11:46AM
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STEINMAN LAWRENCEDirectorJun 01Buy1.2318,00022,06848,129Jun 02 08:00 AM
McGovern Jr. Donald A.DirectorMay 31Buy1.1510,00011,47030,099Jun 01 08:00 AM
McGovern Jr. Donald A.DirectorMay 19Buy1.165,0005,80020,099May 22 08:00 AM
Woody James N.Chief Executive OfficerMay 18Buy1.0340,00041,20041,888May 18 04:40 PM
McGovern Jr. Donald A.DirectorMay 18Buy1.0510,00010,50015,099May 22 08:00 AM
Marrone Pamela GDirectorMay 18Buy1.067,0827,50712,469May 19 08:45 AM
Pamir OzanCFOMay 18Buy1.015,1625,2148,983May 19 08:30 AM